IDEAYA Biosciences, Inc.
NASDAQ:IDYABiotechnology
-$0.45 today
- Market cap
- $2.56B
- Beta
- -0.05
- P/E (TTM)
- -19.5
- EPS (TTM)
- -$1.58
Volume 1.45M
Average 1.44M
IDYA Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
IDEAYA Biosciences, Inc.NASDAQ: IDYA
Gross Margin · Q1 FY2026 · quarter ended Mar 2026
Gross margin at 82.6%
Gross margin was 82.6% in Q1 FY2026. On a trailing-twelve-month basis it was -8.7%, up 943.2 pp year over year. Over 3 fiscal years it widened by 2.0 pp.
Context
- Gross margin widened in 1 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 97.9%
- Year-over-year change
- +52.7pp
| Period | Period end | Gross Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 97.9% | +52.7pp |
| FY2024 | 2024-12-31 | 45.2% | -37.6pp |
| FY2023 | 2023-12-31 | 82.9% | -13.0pp |
| FY2022 | 2022-12-31 | 95.9% | +2.0pp |
| FY2021 | 2021-12-31 | 93.8% | — |
Gross Margin vs competitors
How IDYA compares with its peers on the latest reported figures
- IDYA's LTM Mar 2026 gross margin of -8.7% is the lowest of the 6 companies compared; the peer median is 86.5%.
- Its year-over-year change of +943.2 pp is the highest of 6, against a peer median of -3.7 pp.
- Over three fiscal years its change of +2.0 pp compares with a peer median of -7.2 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 97.7% | -2.3 pp | — | |
| FY2025 | 96.3% | -3.7 pp | -3.7 pp | |
| LTM Aug 2026 | 86.5% | +249.4 pp | +455.2 pp | |
| LTM Mar 2026 | 83.7% | -16.3 pp | -17.1 pp | |
| LTM Mar 2026 | 22.3% | -77.7 pp | -10.8 pp | |
| LTM Mar 2026 | -8.7% | +943.2 pp | +2.0 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding IDYA) | 86.5% | -3.7 pp | -7.2 pp | |
Competitors are the stored peer set for IDYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 27.94M | 50.93M | 23.39M | 7M | 218.71M |
| Cost of Revenue | 1.73M | 2.1M | 4.01M | 3.83M | 4.59M |
| Gross Profit | 26.22M | 48.83M | 19.38M | 3.17M | 214.12M |
| Gross Margin | 93.8% | 95.9% | 82.9% | 45.2% | 97.9% |
| Research & Development | 58.16M | 89.54M | 129.51M | 294.67M | 314.7M |
| Selling, General & Admin | 18.33M | 21.8M | 24.3M | 35.47M | 63.32M |
| Operating Expenses | 76.48M | 111.33M | 153.81M | 330.14M | 373.43M |
| Depreciation & Amortization | 1.73M | 2.1M | 4.01M | 3.83M | 4.59M |
| EBITDA | (48.04M) | (56.55M) | (108.95M) | (270.64M) | (109.11M) |
| EBITDA Margin | -171.9% | -111.0% | -465.9% | -3866.3% | -49.9% |
| Operating Income | (50.27M) | (62.5M) | (134.43M) | (326.98M) | (159.31M) |
| Operating Margin | -179.9% | -122.7% | -574.9% | -4671.1% | -72.8% |
| Interest Income | 506K | 3.85M | 21.47M | 52.5M | 45.62M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 506K | 3.85M | 21.47M | 52.5M | 45.62M |
| Income Before Tax | (49.76M) | (58.66M) | (112.96M) | (274.48M) | (113.7M) |
| Pre-Tax Margin | -178.1% | -115.2% | -483.0% | -3921.1% | -52.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (49.76M) | (58.66M) | (112.96M) | (274.48M) | (113.7M) |
| Net Margin | -178.1% | -115.2% | -483.0% | -3921.1% | -52.0% |
| EPS (Basic) | (1.41) | (1.42) | (1.96) | (3.36) | (1.28) |
| EPS (Diluted) | (1.41) | (1.42) | (1.96) | (3.36) | (1.28) |
| Weighted Avg Shares | 35.25M | 41.44M | 57.52M | 81.68M | 88.49M |
| Weighted Avg Shares (Diluted) | 35.25M | 41.44M | 57.52M | 81.68M | 88.49M |
IDEAYA Biosciences, Inc.
NASDAQ:IDYA
Intrinsic Alpha fair value
Locked
Current Price
$26.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.